Drug intelligence / Profile preview

TI-168

Development stage: Unknown
Lead developer: Baudax Bio
Modality: TCR-Engineered T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
Administration: Intravenous

Overview

TI-168 is an autologous T-cell receptor (TCR) engineered regulatory T-cell (Treg) therapy designed to treat Hemophilia A in patients who have developed inhibitors against Factor VIII (FVIII). Developed by TeraImmune (acquired by Baudax Bio), the therapy utilizes human Tregs engineered with a specific TCR to target and suppress the immune response against FVIII. By inducing immune tolerance, TI-168 aims to eliminate FVIII inhibitors, potentially allowing for the effective use of standard FVIII replacement therapies. The FDA has cleared an Investigational New Drug (IND) application for a Phase 1/2a clinical trial.

Other names: FVIII TCR-Treg

Targets

F8 (Coagulation Factor VIIIa)

Beyond the preview

Go deeper on TI-168.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TI-168.

Explore the full profile